Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 2

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 2
---
 that these events could result in a
variety of risks to the business. The specific impact, if any, is not readily determinable as of the date of these unaudited
condensed consolidated financial statements.

The
Company has based its estimates on assumptions that may prove to be wrong. The Company may need to obtain additional funds sooner or
in greater amounts than it currently anticipates. Potential sources of financing include strategic relationships, public or private sales
of the Company’s shares or debt and other sources. If the Company raises funds by selling additional shares of common stock or
other securities convertible into common stock, the ownership interest of existing stockholders may be diluted.

The
actual amount of funds the Company will need to operate is subject to many factors, some of which are beyond the Company’s control.
These factors include the progress of research activities; the number and scope of research programs; the progress of preclinical and
clinical development activities; the progress of the development efforts of parties with whom the Company has entered into research and
development agreements; the costs associated with additional clinical trials of drug candidates; the ability to maintain current research
and development licensing arrangements and to establish new research and development and licensing arrangements; the ability to achieve
milestones under licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property
rights; and the costs and timing of regulatory approvals.

A
fundamental component of the ability to continue as a going concern is the Company’s ability to raise capital as required, as to
which no assurances can be provided. To address the additional funding requirements of the Company, management has undertaken the following
initiatives:

    ●
    it
    has assessed its current expenditures and will reduce spending where necessary;

    ●
    it
    will pursue additional capital funding in the public and private markets through equity sales and/or debt facilities;

    ●
    it
    will pursue possible partnerships and collaborations; and

    ●
    it
    will pursue potential out licensing for its drug candidates.

The
Company’s ability to continue as a going concern will depend on its ability to raise additional capital, attain further operating
efficiencies, reduce expenditures, and, ultimately, to generate revenue. There are no assurances that these future funding and operating
efforts will be successful. If management is unsuccessful in these efforts, the Company’s current capital is not expected to be
sufficient to fund operations for the next twelve months.

Such conditions raise substantial doubts about the Company’s ability to